BioForce Nanosciences to Collaborate With University Pierre & Marie Curie
13 Noviembre 2008 - 12:10PM
Marketwired
BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a leader in
systems integration at the micro- and nano-scales to create
products for the life sciences, is pleased to announce that it has
signed a scientific collaboration agreement with the University
Pierre & Marie Curie (UPMC) and CNRS (Centre National de
Recheche Scientifique) in Paris, France. Under the terms of this
agreement, researchers from the laboratory of Dr. Fatiha Nothias
will collaborate with BioForce to develop technologies, protocols,
and products related to neural cell-based assays.
These proprietary assays will be created using the Nano
eNabler(TM) molecular printer from BioForce, and they will allow
scientists to study the structure, function, and microenvironments
of neural cells. In particular, neural cell-based assays hold great
promise as a platform for evaluating the therapeutic potential of
new drug compounds and treatments for neurodegenerative diseases
and neural trauma.
Dr. Fatiha Nothias, Principal Investigator at UPMC, said, "This
novel molecular micro-printing device appears to be a very useful
and flexible technology to bring new insights into the cellular
response processes, such as proliferation, apoptosis,
morphogenesis, and differentiation. In particular, we are focusing
on axonal outgrowth in the nervous system, which is controlled by
specific extracellular cues that exhibit a precise spatial and
temporal distribution, allowing the axon to reach its target.
Mimicking in vitro, at least partially, the in vivo environment, is
a big challenge. Thus it is a great opportunity for us to
collaborate with BioForce. We are very enthusiastic in using the
Nano eNabler system to investigate how growth cones (highly motile
distal tip of the neuronal axon) are sensing and are influenced by
micropatterned substrates."
BioForce's Product Manager, Michael Lynch, said, "We have
enjoyed working closely with Dr. Nothias and the UMPC over the past
two years as they have pushed the capabilities of our Nano eNabler
technology. This collaborative agreement emphasizes our continued
interest in supporting cutting edge applications and bringing them
to the market as novel products. The biomedical research community
has made fantastic advances in a number of areas, however, there
are still a great many unknowns in brain research, and deciphering
that complexity represents a massive international effort and
opportunity. As an example, there are nearly 40,000 members of the
Society for Neuroscience working around the globe to unravel the
mysteries of the human brain. We believe that our products are the
type of tools that these researchers need in order to unlock the
mysteries of the human brain, and develop therapies that more
effectively treat neural disorders."
On November 18, Dr. Fatiha Nothias will be presenting her most
recent results at the Society for Neuroscience 2008 conference in
Washington, DC. The title of her talk is "Micropatterned Adhesive
Extracellular Matrix Substrates Reveal Specific Response of DRG
Neuron Growth Cone." BioForce Nanosciences will also be presenting
a research poster at the same conference, titled, "Basolateral
Activation of Neural Crest-Derived PC-12 Cells." An electronic copy
of this poster may be downloaded from the BioForce Resources
Library after it has been presented. Representatives from BioForce
will be available in the Society for Neuroscience exhibit hall at
booth #1206.
BioForce Nanosciences will also be exhibiting at TERMIS 2008
(Tissue Engineering & Regenerative Medicine International
Society) in San Diego, CA on December 7-10, and the American
Society for Cell Biology in San Francisco, CA on December
13-17.
For further information about this release please contact Greg
Brown, Chief Financial Officer of BioForce at (515) 233-8333 ext.
118, or Rich Kaiser, Investor Relations at (800) 631-8127.
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences creates products and solutions for the
life sciences by integrating biological and mechanical systems at
the micro and nano scales. BioForce's flagship product, the Nano
eNabler(TM) molecular printer, gives the Company and its customers
a platform for development and discovery by printing tiny domains
of biological materials on surfaces with nanometer spatial
precision. BioForce technology is being used in areas such as
biosensor functionalization; patterning and cell adhesion; and the
printing of proteins to guide neural cell growth. For more
information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may
be affected by certain risks and uncertainties, including those
risks and uncertainties described in BioForce Nanosciences' most
recent filings with the Securities and Exchange Commission.
BioForce Nanosciences' actual results could differ materially from
such forward-looking statements. BioForce assumes no duty to update
these statements at any future date.
Contacts: Company Contact Gregory D. Brown Chief Financial
Officer 515-233-8333 ext# 118 Email Contact Investor Relations Yes
International Rich Kaiser 800-631-8127
BioForce Nanosciences (PK) (USOTC:BFNH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
BioForce Nanosciences (PK) (USOTC:BFNH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024